ArticleACS medicinal chemistry letters2025
Salt-Tolerant, Protease-Stable and Non-Resistance Developing Cationic AMPs for Combatting Planktonic MRSA and its Biofilms.
Article in ACS medicinal chemistry letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- Defensins as natural antimicrobial peptide scaffolds against antimicrobial-resistant pathogens: mechanisms, resistance risks, and translational prospects.Frontiers in cellular and infection microbiology · 2026Review
- Impact of the Arrangement Modes of the Antimicrobial Motifs WWR-7 and its Analogs in CAMPs on Their Therapeutic Properties.Chemistry, an Asian journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global antimicrobial resistance crisis has stimulated the development of innovative therapeutics. Methicillin-resistant Staphylococcus aureus (MRSA), a critical pathogen responsible for skin and soft tissue infections. MRSA biofilms exhibit greater resistance to antibiotics compared to planktonic cells. Antimicrobial peptides (AMPs) are potential alternatives but face challenges like high costs, salt sensitivity, toxicity, and protease degradability. This study developed highly potent, salt-tolerant, nontoxic, and proteolytically stable membranolytic AMPs: d-WRL (composed of all d-amino acids) and W-(Dab)-L (incorporating 2,4-diaminobutyric acid), which effectively prevented planktonic MRSA, inhibited biofilm formation, and eradicated ∼80% of mature biofilms, outperforming vancomycin with faster killing kinetics. The biofilm eradication ability was attributed to their protease stability. The developed AMPs prevented resistance development in MRSA over 96 generations, unlike ciprofloxacin, and thus are critical additions to the limited arsenal of potential MRSA-targeting therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.